Open Access

MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer

Retraction in: /10.3892/mmr.2023.13130

  • Authors:
    • Woda Shi
    • Jianxiang Song
    • Wencai Wang
    • Yajun Zhang
    • Shiying Zheng
  • View Affiliations

  • Published online on: September 19, 2017     https://doi.org/10.3892/mmr.2017.7517
  • Pages: 7329-7336
  • Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑small‑cell lung cancer (NSCLC) accounts for ~80% of human lung cancers that result in mortalities worldwide. Metastasis‑associated in colon cancer‑1 (MACC‑1) has been demonstrated to be significantly expressed in cases of NSCLC and promotes tumor cell migration and metastasis through transactivation of the metastasis‑inducing hepatocyte growth factor/MET proto‑gene, receptor tyrosine kinase (HGF/MET) signaling pathway. The present study constructed a chimeric antibody (Chanti‑MACC‑1) targeting MACC‑1 and investigated its potential as a molecular therapeutic target in the treatment of NSCLC therapy. The expression of MACC‑1 was detected by reverse transcription‑quantitative polymerase chain reaction and western blotting in lung cancer cell lines and tissues. MTT assay was used to detect proliferation of A549 cells treated by Chanti‑MACC‑1, whereas the functional and regulatory effects of Chanti‑MACC‑1 in the migration and metastasis of NSCLC cells was investigated by a cell invasion assay. The therapeutic effect and survival time was observed in animal models. The results demonstrated that MACC‑1 expression was increased and overexpression of MACC‑1 promoted the progression of the cell cycle, significantly promoted NSCLC cell growth and enhanced tumor migration and invasion through the HGF/MET signaling pathway. It was further demonstrated that Chanti‑MACC‑1 efficiently suppressed MACC‑1 expression and significantly inhibited NSCLC cell proliferation, migration and invasion by blocking the HGF/MET signaling pathway. The data revealed that Chanti‑MACC‑1 was not only beneficial for tumor remission, however additionally contributed to the long‑term survival of NSCLC ‑bearing mice. The findings of the present study indicated that MACC‑1 was significantly upregulated and promoted tumor cell growth and migration in NSCLC cells and tissues via transactivation of the metastasis‑inducing HGF/MET signaling pathway. However, Chanti‑MACC‑1significantly inhibited tumor growth and metastasis, which suggested that MACC‑1 may be essential for tumor initiation and progression by negatively regulating tumor suppressors.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 16 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shi W, Song J, Wang W, Zhang Y and Zheng S: MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer Retraction in /10.3892/mmr.2023.13130. Mol Med Rep 16: 7329-7336, 2017
APA
Shi, W., Song, J., Wang, W., Zhang, Y., & Zheng, S. (2017). MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer Retraction in /10.3892/mmr.2023.13130. Molecular Medicine Reports, 16, 7329-7336. https://doi.org/10.3892/mmr.2017.7517
MLA
Shi, W., Song, J., Wang, W., Zhang, Y., Zheng, S."MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer Retraction in /10.3892/mmr.2023.13130". Molecular Medicine Reports 16.5 (2017): 7329-7336.
Chicago
Shi, W., Song, J., Wang, W., Zhang, Y., Zheng, S."MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer Retraction in /10.3892/mmr.2023.13130". Molecular Medicine Reports 16, no. 5 (2017): 7329-7336. https://doi.org/10.3892/mmr.2017.7517